Investors
Investor relations
Latest news
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Change in number of shares and votes in Camurus
Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism
Corporate presentation
-
12Feb
Full Year Report 2025
The full year report 2025 is published on 12 February 2026.
-
12Feb
Interim Report January-December 2025 – Webcast
Financial analysts, investors and media are invited to attend a webcast and presentation of the results at 2.00 pm CET.
Access the webcast using this link: Webcast
To participate in the presentation and ask questions, please register using the link below. After registering, please use the provided phone number and conference ID to dial in. Register to dial in
-
11Mar
Danske Bank Small & Mid Cap Seminar
Camurus’ President & CEO Fredrik Tiberg is presenting at this conference in Stockholm, 11 March. The presentation can be seen by the conference participants. More information will follow closer to the event.
Latest financial report
Camurus’ Interim Report Third Quarter 2025
6 November 2025
CEO statement Q3 2025
”High profitability and launch preparations for Oczyesa®”
ESG rankings
Camurus has an ambitious sustainability agenda with the aim of improving the company’s sustainability performance and contribution to the UN’s Sustainable Development Goals. Our performance and progress is regularly evaluated by independent third-party ESG ratings.
Nasdaq Transparency Partner
Since 2022, Camurus is a Nasdaq ESG Transparency Partner. The certification demonstrates Camurus’ commitment to market transparency and raising environmental standards.
Investor contact
IPO and Prospectus
subscribe
Get the latest news from Camurus
Subscribe to receive latest news from Camurus driectly to your email.
